{"entity":{"id":"nct07669454","kind":"trial","name":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.","aka":[],"tldr":"A phase 3 trial of Nuvastatic 300 in colorectal cancer, run by Natureceuticals Sdn Bhd, now recruiting.","summary":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy. is a phase 3 interventional study registered as NCT07669454 by Natureceuticals Sdn Bhd, with 250 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-10-31. Interventions recorded: Nuvastatic 300 and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07669454","url":"https://clinicaltrials.gov/study/NCT07669454"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07669454","phase":"3","setting":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.","sponsor":"Natureceuticals Sdn Bhd","enrolled":250,"outcomes":[]},"route":"/trials/nct07669454/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}